PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models
Brain · 07.04.2026 · 149 (4) · 1289-1301
DOI: 10.1093/brain/awaf372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 16.10.2025. Verfasst von Eduardo A Albornoz und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane 4072, Australia. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Parkinson Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC, Michael J Fox Foundation, Shake it Up Australia Foundation.
Abstract (Originalsprache)
Parkinson’s disease is one of the fastest-growing neurodegenerative disorders, with no effective treatments to modify its progression. Microglial-driven neuroinflammation, mediated by NOD-leucine rich repeat and pyrin containing protein 3 (NLRP3) inflammasome activation, plays a key role in disease onset and progression. The NLRP3 inflammasome is upregulated in microglia from Parkinson’s disease patients and activated by oxidative stress and α-synuclein aggregates, triggering the release of pro-inflammatory mediators that contribute to neuroinflammation and neuronal death. MCC950, the first described specific NLRP3 inhibitor, has shown promise in Parkinson’s disease models but is limited by suboptimal pharmacokinetics and safety, hindering its clinical development. Here, we developed a novel NLRP3 inflammasome inhibitor, MCC7840 (also known as Inzomelid or Emlenoflast), and utilized clinically relevant PET-MRI imaging biomarkers to assess its therapeutic efficacy in preclinical models of Parkinson’s disease. MCC7840 inhibited NLRP3 in human and mouse microglia with nanomolar potency, while demonstrating improved systemic exposure, half-life, brain permeability and bioavailability compared with MCC950. In a murine NLRP3 gain-of-function model of Muckle–Wells syndrome, MCC7840 effectively inhibited mortality and demonstrated superior potency compared with MCC950. Chronic oral administration of MCC7840 protected against neuroinflammation, motor deficits and dopamine loss in both 6-hydroxydopamine and preformed α-synuclein fibril mouse models of Parkinson’s disease. Radiotracer imaging of multiple PET markers in the same mouse revealed that MCC7840 attenuated neuroinflammation (translocator protein ligand; 18F-DPA-714), preserved dopamine uptake (fluorodopa; 18F-FDOPA), mitigated dopamine transporter (DAT) loss (DAT ligand; 18F-FBCTT) and reduced blood–brain barrier leakage (gadolinium contrast MRI). Notably, MCC7840 was effective in a slowly progressing 12-month α-synuclein model, even when administered after symptom onset, 4 months post-α-synuclein injection. These findings highlight the utility of PET/MRI as a non-invasive tool to evaluate drug efficacy and support MCC7840, and other brain-penetrant NLRP3 inhibitors, as promising disease-modifying therapies for Parkinson’s disease, warranting future clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane 4072, Australia.
- Centre for Advanced Imaging, The University of Queensland, Brisbane 4072, Australia.
- The Institute for Molecular Bioscience, The University of Queensland, Brisbane 4072, Australia.
- Translational Research Institute (TRI), School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia.
- The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
- Inflazome Ltd, Welwyn Garden City AL7 1TW, UK.
ORCID-Profile: Trent M Woodruff
Förderung
- NHMRC
- Michael J Fox Foundation
- Shake it Up Australia Foundation
- Australia India Strategic Research Fund
- Inflazome Ltd
Zitieren
APA
Albornoz, E. A., Mardon, K., Bhalla, R., Kumar, V., Stimson, D. H. R., Cowin, G., Cui, C. S., Butler, M. S., Pelingon, R., Gordon, R., Coll, R. C., Schroder, K., Halai, R., MacLeod, A. M., Matthews, K., Robertson, A. A. B., Cooper, M. A., & Woodruff, T. M. (2026). PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models. Brain, 149(4), 1289-1301. https://doi.org/10.1093/brain/awaf372
Vancouver
Albornoz EA, Mardon K, Bhalla R, Kumar V, Stimson DHR, Cowin G, et al. PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models. Brain. 2026;149(4):1289-1301. doi:10.1093/brain/awaf372
BibTeX
@article{Albornoz2026,
author = {Albornoz, Eduardo A and Mardon, Karine and Bhalla, Rajiv and Kumar, Vinod and Stimson, Damion H R and Cowin, Gary and Cui, Cedric S and Butler, Mark S and Pelingon, Ruby and Gordon, Richard and Coll, Rebecca C and Schroder, Kate and Halai, Reena and MacLeod, Angus M and Matthews, Kim and Robertson, Avril A B and Cooper, Matthew A and Woodruff, Trent M},
title = {PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models},
journal = {Brain},
year = {2026},
volume = {149},
number = {4},
pages = {1289--1301},
doi = {10.1093/brain/awaf372}
}
EUVIMED